Compare NPCE & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPCE | ZVRA |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 623.0M | 653.2M |
| IPO Year | 2021 | 2015 |
| Metric | NPCE | ZVRA |
|---|---|---|
| Price | $16.31 | $10.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.33 | ★ $23.00 |
| AVG Volume (30 Days) | 199.4K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.03 | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | $99,986,000.00 | ★ $106,470,000.00 |
| Revenue This Year | $0.90 | $37.27 |
| Revenue Next Year | $24.46 | $53.42 |
| P/E Ratio | ★ N/A | $17.06 |
| Revenue Growth | 25.13 | ★ 350.91 |
| 52 Week Low | $7.56 | $7.16 |
| 52 Week High | $19.60 | $13.16 |
| Indicator | NPCE | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 47.37 |
| Support Level | $15.17 | $8.30 |
| Resistance Level | $17.04 | $11.07 |
| Average True Range (ATR) | 1.17 | 0.62 |
| MACD | -0.24 | -0.08 |
| Stochastic Oscillator | 42.86 | 12.44 |
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.